<SEC-DOCUMENT>0001125345-19-000061.txt : 20190501
<SEC-HEADER>0001125345-19-000061.hdr.sgml : 20190501
<ACCEPTANCE-DATETIME>20190501160828
ACCESSION NUMBER:		0001125345-19-000061
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190331
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190501
DATE AS OF CHANGE:		20190501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		19787520

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-kq12019earningsp.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:14pt;font-weight:700;line-height:120%;">UNITED STATES</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:14pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;"> WASHINGTON, D.C. 20549</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">____________________</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">FORM 8-K</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CURRENT REPORT</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;"> Pursuant to Section 13 or 15(d) of the</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Securities Exchange Act of 1934</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Date of report (Date of earliest event reported)&#58;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">May&#160;1, 2019</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:16pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (Exact Name of Registrant as Specified in Charter)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:32.948605%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.102790%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.948605%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Delaware</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">001-36112</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">06-1591613</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">(State or Other Jurisdiction</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">of Incorporation)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">(Commission</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"> File Number)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">(IRS Employer</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"> Identification No.)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:62.516129%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:33.483871%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">9704 Medical Center Drive,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Rockville, Maryland</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20850&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">(Address of Principal Executive Offices)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">(Zip Code)</font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Registrant's telephone number, including area code&#58;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(301) 251-5172</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Not applicable&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)&#58;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#91;&#160; &#93; Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#91;&#160; &#93; Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#91;&#160; &#93; Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#91;&#160; &#93; Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:18pt;margin-top:5pt;margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </font></div><div style="margin-top:5pt;margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Emerging growth company  &#9744;</font></div><div style="text-indent:18pt;margin-top:5pt;margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:14.422287%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:81.577713%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Item 2.02</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Results of Operations and Financial Condition</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">May&#160;1, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">,  the Company announced financial and operating results as of and for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">March&#160;31, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed &#34;filed&#34; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#34;Exchange Act&#34;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:14.200295%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:81.799705%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Item 9.01</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Financial Statements and Exhibits</font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:14.568915%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:81.431085%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(d) Exhibits.</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:14.200295%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:81.799705%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Exhibit Number</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Description of Exhibit</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">99.1&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="exhibit99-1earningspre.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;">Press Release dated May 1, 2019</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURE</font></div><div style="text-indent:36pt;margin-top:3pt;margin-bottom:3pt;"><font><br></font></div><div style="text-indent:36pt;margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="text-indent:36pt;margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:47.045521%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.607930%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.346549%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 1, 2019</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">MACROGENICS, INC.</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Jeffrey Peters</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Jeffrey Peters</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Vice President and General Counsel</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1earningspre.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Exhibit 99.1</font></div></div><div><font><br></font></div><div style="text-align:center;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">Conference call scheduled </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">today at 4&#58;30 p.m. ET</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">ROCKVILLE, Md., May 1, 2019 (GLOBE NEWSWIRE)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> -- MacroGenics, Inc. (NASDAQ&#58; MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended March 31, 2019.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8220;In February, we reported topline results from SOPHIA showing that in the Phase 3 trial, progression-free survival was prolonged following treatment with margetuximab and chemotherapy compared to trastuzumab with chemotherapy. We look forward to presenting detailed results at ASCO. In addition, we </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">anticipate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> submit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">ting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> a BLA for this program to the FDA in the second half of 2019. If approved by regulators, margetuximab could offer the potential of a new treatment option for patients living with HER2-positive metastatic breast cancer in a third line and beyond setting where there are currently no FDA-approved therapies. In seeking to address unmet needs of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">pat</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">ients </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">HER2-postive cancers beyond breast cancer, we plan to initiate in the second half of 2019 a registration-directed trial to evaluate margetuximab for treating gastric cancer patients in the frontline setting,&#8221; said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8220;Mechanistically, we believe the results achieved in the SOPHIA study have validated our Fc-optimization technology, also used in enoblituzumab, our investigational monoclonal antibody targeting B7-H3,&#8221; continued Dr. Koenig. &#8220;To date, we have made tremendous progress with our immuno-oncology pipeline of nine clinical product candidates with multiple molecules demonstrating clinical proof of concept to support ongoing and&#47;or planned registration studies.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">Key Pipeline Updates</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">Margetuximab. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">Recent updates related to the Company&#8217;s investigational Fc-optimized monoclonal antibody (mAb) that targets human epidermal growth factor receptor 2 (HER2) include&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">Oral Presentation of SOPHIA Data at ASCO&#59; Plans to Submit BLA in 2H2019&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">In February 2019, MacroGenics announced that SOPHIA, the Phase 3 clinical trial of margetuximab in patients with HER2-positive metastatic breast cancer, met the trial&#8217;s first </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">sequential </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">primary endpoint of prolongation of progression-free survival (PFS) in patients treated with the combination of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy. An abstract containing data from</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">SOPHIA was selected for presentation in an oral session to be held on Tuesday, June 4, 2019 at the American Society of Clinical Oncology (ASCO) Annual Meeting. MacroGenics anticipates submitting a Biologics License Application (BLA) to the U.S. FDA for margetuximab, based on the PFS results, in the second half of 2019. </font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">Additional Validating Mechanistic Data in Poster</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">s</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;"> at </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">AACR and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">ASCO&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">D</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">ata presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2019 showed improved Fc-dependent activity of margetuximab compared to trastuzumab in vitro</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">These preclinical data </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">validat</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">e</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> the molecule&#8217;s underlying mechanism of action and the Company&#8217;s Fc-optimization platform. In addition, an abstract containing data describing HER2-specific immunity observed in patients with HER2-positive cancers treated with margetuximab in the Phase 1 trial was selected for presentation in a poster session at ASCO on Sunday, June 2, 2019.</font></div><div style="position:relative;width:100%;height:36pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Exhibit 99.1</font></div></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">Plans to Initiate Front-line Gastric Cancer Trial in 2H2019&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">At the ASCO Gastrointestinal Cancers Symposium in January 2019, data were presented demonstrating</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">encouraging anti-tumor activity and acceptable safety and tolerability of margetuximab in combination with an anti-PD-1 mAb in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">a</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> Phase 2 clinical trial in patients with HER2-positive gastric or gastroesophageal junction cancer. MacroGenics and its partner in Greater China, Zai Lab, expect to initiate a Phase 2&#47;3 registration-directed clinical trial of margetuximab in combination with checkpoint inhibitor molecules, including MGA012 (anti-PD-1 mAb) and MGD013 (bispecific PD-1 x LAG-3 DART&#174; molecule) in the second half of 2019.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">B7-H3 Franchise. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">MacroGenics is developing a portfolio of investigational antibody-based therapeutics that target B7-H3 through complementary mechanisms of action taking advantage of this antigen's broad expression across multiple solid tumor types. Recent program highlights include&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">Plans to Advance Enoblituzumab in Head and Neck Cancer Study&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> Enoblituzumab is an Fc-optimized mAb that targets B7-H3. Encouraging data from the Phase 1 clinical study of enoblituzumab in combination with an anti-PD-1 mAb were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2018. Based on these data, MacroGenics is planning to initiate a Phase 2 study of enoblituzumab in combination with MGA012 in patients with squamous cell carcinoma of the head and neck (SCCHN) in the second half of 2019.</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">MGD009 Phase 1 Studies Ongoing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#58; MGD009 is a bispecific DART molecule designed to target B7-H3 expressed on tumor cells and CD3 expressed on normal T cells. MacroGenics is enrolling patients in two Phase 1 clinical trials of MGD009, one as monotherapy and another in combination with MGA012.</font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">MGC018 Dose Escalation Ongoing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#58; MGC018 is an antibody-drug conjugate (ADC) designed to target solid tumors expressing B7-H3. MacroGenics is evaluating MGC018 in a Phase 1 dose escalation study.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">PD-1 Franchise</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">. MacroGenics </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">is</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> advancing multiple investigational PD-1-directed programs to provide differentiation from existing PD-1-based treatment options and enable a broad set of combination opportunities across the Company&#8217;s portfolio. Recent program highlights include&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">MGA012 Registration-directed Studies Ongoing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#58; MGA012 (INCMGA0012) is an anti-PD-1 mAb exclusively licensed to Incyte </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">Corporation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">on a worldwide basis. Incyte is initially pursuing development of MGA012 monotherapy through three potentially registration-directed trials in MSI-high endometrial cancer, Merkel cell carcinoma and anal cancer and</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> Incyte and MacroGenics are each conducting multiple studies of MGA012 in combination with other agents. MacroGenics retains the right to develop its pipeline of product candidates in combination with MGA012.</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">MGD013 Dose Expansion Ongoing&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> MGD013 is a first-in-class bispecific DART molecule designed to provide co-blockade of PD-1 and LAG-3, two immune checkpoint molecules expressed on T cells. MacroGenics is evaluating MGD013 in a Phase 1 dose expansion study in up to nine tumor types and expects to present data from this trial in the second half of 2019.</font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">MGD019 Dose Escalation Ongoing&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> MGD019 is a bispecific DART molecule designed to provide co-blockade of PD-1 and CTLA-4, two immune checkpoint inhibitors expressed on T cells. MacroGenics is currently evaluating MGD019 in a Phase 1 dose escalation study.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">Flotetuzumab.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">A </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">r</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">ecent update</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> related to the Company&#8217;s investigational, bispecific DART molecule that recognizes both CD123 and CD3, include</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">s</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:30.53pt;">Data from Ongoing Study Expected 2H2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#58; Based on data presented at the American Society of Hematology (ASH) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">nnual </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">M</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">eeting in December 2018 showing anti-leukemic activity and acceptable tolerability of flotetuzumab in patients with relapsed&#47;refractory AML, MacroGenics is enrolling additional patients in a dose expansion cohort enriched for primary refractory patients and expects to announce updated data from the trial in the second half of 2019. The Company&#8217;s collaborator, Servier, has development and commercialization rights outside North America, Japan, Korea and India for flotetuzumab, also known as S80880.</font></div><div style="margin-bottom:6pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">First</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;"> Quarter </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">201</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;"> Financial Results</font></div><div style="position:relative;width:100%;height:36pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Exhibit 99.1</font></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;padding-left:12.53pt;">Cash Position</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">&#58; Cash, cash equivalents and marketable securities as of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">March&#160;31, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">, were </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">$320.4 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">, compared to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">$232.9 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;"> as of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">December&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt;">Revenue</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#58; Total revenue, consisting primarily of revenue from collaborative agreements, was </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">$9.7 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">March&#160;31, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">, compared to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">$4.7 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">March&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">Revenue from collaborative agreements included revenue received under a clinical supply agreement with Incyte, as well as the recognition of deferred revenue from payments received in previous periods and payments received during the quarter.</font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt;">R&#38;D Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#58; Research and development expenses were </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">$47.1 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">March&#160;31, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">, compared to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">$45.7 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">March&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">. This </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">increase</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">w</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">as due</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> to increased clinical trial costs for MGD013, MGC018 and flotetuzumab, as well as increased development&#47;manufacturing costs related to MGA012 (largely offset by revenue from Incyte). These increases were partially offset by decreased expenses related to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">SOPHIA and enoblituzumab clinical studies.</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;padding-left:12.53pt;">G&#38;A Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">&#58; General and administrative expenses were </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">$10.2 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;"> for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">March&#160;31, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">, compared to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">$9.2 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;"> for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">March&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">. </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;padding-left:12.53pt;">Net Loss</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">&#58; Net loss was </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">$45.0 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;"> for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">March&#160;31, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">, compared to net loss of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">$49.5 million</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;"> for the quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">March&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;padding-left:12.53pt;">Shares Outstanding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">&#58; Shares outstanding as of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">March&#160;31, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;"> were </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">48,805,008</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:138%;">.</font></div><div style="text-indent:18pt;margin-top:9pt;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">Conference Call Information</font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">MacroGenics will host a conference call today at 4&#58;30 p.m. ET to discuss financial results for the quarter ended March 31, 2019 and provide a corporate update. To participate in the conference call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and provide the Conference ID&#58; 8788605.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">The listen-only webcast of the conference call can be accessed under &#34;Events &#38;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> Presentations&#34; in the Investor Relations section of the Company's website at http&#58;&#47;&#47;ir.macrogenics.com&#47;events.cfm. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">MACROGENICS, INC.</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">SELECTED CONSOLIDATED BALANCE SHEET DATA</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">(Amounts in thousands)</font></div><div style="text-align:center;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.196262%;"><tr><td style="width:1.0%;"></td><td style="width:45.916667%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.641026%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:23.641026%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">320,391&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">232,863&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">414,638&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">332,130&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">35,292&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">40,722&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">320,617&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">242,877&#160;</font></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:36pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Exhibit 99.1</font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:138%;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:174%;">(Unaudited)</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:174%;">(Amounts in thousands, except share and per share data)</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:65.912773%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.109034%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.578816%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.199377%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:700;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:700;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:700;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-78pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:400;line-height:100%;">Revenue from collaborative agreements</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">9,497&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">4,501&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-84pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:400;line-height:100%;">Revenue from government agreement</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">165&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">194&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">9,662&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">4,695&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-90pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:400;line-height:100%;">Research and development</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">47,060&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">45,670&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-96pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:400;line-height:100%;">General and administrative</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">10,219&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">9,235&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">57,279&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">54,905&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,617)</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,210)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">2,600&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">674&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,017)</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,536)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;padding-right:-102pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:400;line-height:100%;">Unrealized gain</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:400;line-height:100%;"> on investments</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">39&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,014)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,497)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.99)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.34)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted average common shares outstanding</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">45,606,651&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Calibri;color:#000000;background-color:rgb(255,255,255, 0.0);">36,936,560&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><font><br></font></div><div style="position:relative;width:100%;height:36pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Exhibit 99.1</font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:120%;">About MacroGenics, Inc.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, DART&#174; and TRIDENT are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">Cautionary Note on Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words &#34;subject to&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;plan&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;estimate&#34;, &#34;project&#34;, &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;would&#34;, &#34;could&#34;, &#34;can&#34;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;font-weight:700;line-height:115%;">Contacts&#58;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">MacroGenics, Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">Jim Karrels, Senior Vice President, CFO</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">Anna Krassowska, Ph.D., Vice President, Investor Relations &#38;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;"> Corporate Communications</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">1-301-251-5172, info&#64;macrogenics.com</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">MacDougall Biomedical Communications</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">Karen Sharma, Senior Vice President</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Calibri;font-size:11pt;line-height:115%;">1-781-235-3060, ksharma&#64;macbiocom.com</font></div><div style="position:relative;width:100%;height:36pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
